Richcore Lifesciences

richcoreindia.com

Richcore Lifesciences Pvt. Ltd. is an innovation led biotechnology company developing novel enzymatic solutions for Industrial Biotechnology and Animal Origin Free recombinant proteins and enzymes for Biopharma. Richcore is venture and PE investment backed, and has multiple patent filings, and a high capacity GMP certified manufacturing plant. Its solutions are used in the global food, water, energy, and biopharma industries. At the root of its innovation is the vision and commitment to create cleaner, greener and sustainable solutions to tackle the current industrial problems. Richcore's corporate goals are aligned with the goals of the society at large to achieve meaningful economic development. Richcore intrinsically believes that doing well happens by doing good!

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ENZO BIOCHEM’S FULL SERVICE CLINICAL LABORATORY TO LAUNCH CORONAVIRUS (COVID-19) TESTING SERVICES NEXT WEEK

Biotechnology news | March 06, 2020

news image

Enzo Biochem, Inc. (NYSE:ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc., will begin accepting specimens for novel Coronavirus (COVID-19) testing next week. COVID-19 is a contagious virus that is believed to spread by person-to-person transmission and may have serious health consequences. The virus has infected more than 93,000 people globally including recent detections in the United States. Enzo has many years of experience processing specimens for the detection...

Read More

Cell and Gene Therapy

BIOCENTRIQ® AND KYTOPEN® EXPAND PARTNERSHIP TO EXPEDITE IMPACT OF TRANSFORMATIVE GENE-EDITING TECHNOLOGY ON CELL THERAPY MANUFACTURING

PRNewswire | June 12, 2023

news image

BioCentriq®, a strategic CDMO specializing in cell therapy announced that it has expanded its partnership with Kytopen, a Cambridge based startup spun out of Massachusetts Institute of Technology (MIT). The partnership was originally announced in March of 2021. In the initial phase of the collaboration, the Kytopen and BioCentriq teams worked together to test transfection of T-cells using Kytopen's Flowfect® technology and the potential impact to both autologous and ...

Read More

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

news image

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More

Industrial Impact

XILIO THERAPEUTICS TO HOST LIVE VIRTUAL PROGRAM SPOTLIGHTING XTX301, A TUMOR-ACTIVATED IL-12

Xilio Therapeutics, Inc. | November 28, 2022

news image

Xilio Therapeutics, Inc. a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, announced that the company will host a live virtual program on Thursday, December 1, 2022, at 12:30 p.m. ET spotlighting Xilio’s clinical-stage molecule XTX301, a tumor-activated, engineered IL-12. The event will feature Diwakar Davar, MBBS, M.Sc., a key opinion leader and assistant professor of medicine and a medical oncologist/hematologist fr...

Read More
news image

ENZO BIOCHEM’S FULL SERVICE CLINICAL LABORATORY TO LAUNCH CORONAVIRUS (COVID-19) TESTING SERVICES NEXT WEEK

Biotechnology news | March 06, 2020

Enzo Biochem, Inc. (NYSE:ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc., will begin accepting specimens for novel Coronavirus (COVID-19) testing next week. COVID-19 is a contagious virus that is believed to spread by person-to-person transmission and may have serious health consequences. The virus has infected more than 93,000 people globally including recent detections in the United States. Enzo has many years of experience processing specimens for the detection...

Read More
news image

Cell and Gene Therapy

BIOCENTRIQ® AND KYTOPEN® EXPAND PARTNERSHIP TO EXPEDITE IMPACT OF TRANSFORMATIVE GENE-EDITING TECHNOLOGY ON CELL THERAPY MANUFACTURING

PRNewswire | June 12, 2023

BioCentriq®, a strategic CDMO specializing in cell therapy announced that it has expanded its partnership with Kytopen, a Cambridge based startup spun out of Massachusetts Institute of Technology (MIT). The partnership was originally announced in March of 2021. In the initial phase of the collaboration, the Kytopen and BioCentriq teams worked together to test transfection of T-cells using Kytopen's Flowfect® technology and the potential impact to both autologous and ...

Read More
news image

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More
news image

Industrial Impact

XILIO THERAPEUTICS TO HOST LIVE VIRTUAL PROGRAM SPOTLIGHTING XTX301, A TUMOR-ACTIVATED IL-12

Xilio Therapeutics, Inc. | November 28, 2022

Xilio Therapeutics, Inc. a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, announced that the company will host a live virtual program on Thursday, December 1, 2022, at 12:30 p.m. ET spotlighting Xilio’s clinical-stage molecule XTX301, a tumor-activated, engineered IL-12. The event will feature Diwakar Davar, MBBS, M.Sc., a key opinion leader and assistant professor of medicine and a medical oncologist/hematologist fr...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us